Cargando…
23andMe: a new two-sided data-banking market model
BACKGROUND: Since 2006, the genetic testing company 23andMe has collected biological samples, self-reported information, and consent documents for biobanking and research from more than 1,000,000 individuals (90 % participating in research), through a direct-to-consumer (DTC) online genetic-testing...
Autores principales: | Stoeklé, Henri-Corto, Mamzer-Bruneel, Marie-France, Vogt, Guillaume, Hervé, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826522/ https://www.ncbi.nlm.nih.gov/pubmed/27059184 http://dx.doi.org/10.1186/s12910-016-0101-9 |
Ejemplares similares
-
Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine
por: Stoeklé, Henri-Corto, et al.
Publicado: (2017) -
Comparison of Commercial Genetic-Testing Services in Korea with 23andMe Service
por: Kim, Sollip, et al.
Publicado: (2014) -
Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe
por: Lu, Mengfei, et al.
Publicado: (2017) -
The law and problematic marketing by private umbilical cord blood banks
por: Murdoch, Blake, et al.
Publicado: (2020) -
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response
por: Li, Q S, et al.
Publicado: (2016)